Abstract
Asthma maintenance treatment aims to preserve asthma control in order to reduce the risk of asthma exacerbation. The combination between an inhaled corticosteroid and a fast-acting bronchodilator, systemic corticosteroids (SCS) bursts and other add-on asthma medications are prescribed for asthma worsening to mitigate serious outcomes.1 Primary findings from a 26-week double-blind, randomized-controlled trial in patients ≥12 years of age with persistent asthma comparing mometasone furoate/formoterol (MF/F) to MF did not demonstrate a significant difference in asthma-related hospitalizations, intubations and deaths, but did show a significant reduction in asthma exacerbation.2 The present analysis of additional prespecified endpoints further characterizes MF/F effects on clinical measures of asthma control.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
